| P/E (FY) | — | Sales (TTM) | $55.5M |
| Earnings (TTM) | -$180.4M | ROE | — |
| Net Margin | −351.49% | ROIC | — |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Gossamer Bio is a clinical-stage biopharmaceutical company developing and commercializing seralutinib for pulmonary hypertension and pulmonary arterial hypertension in the United States. Its lead candidate, GB002, is an inhaled small-molecule inhibitor of PDGFR, colony-stimulating factor 1 receptor, and c-KIT, in Phase 3 trials for PAH. The company holds license agreements with Pulmokine to develop and commercialize GB002 and related backup compounds.
| Market Cap | $48.1M | Trading Days | 1871 |
| 52W High | 3.87 |
| 52W Low | 0.11 |
| % Off High | −94.70% |
| YTD | −93.38% | 1Y | −89.64% |
| 3Y | −83.98% | 5Y | −97.39% |
| Since incept. (ann.) | −45.06% |
Reporting 100%
| Ann. Volatility (1Y) | 141.22% | Ann. Volatility (3Y) | 107.91% |
| Sharpe (1Y) | −0.57 | Sharpe (3Y) | 0.13 |
| Max Drawdown (1Y) | −96.41% | Max Drawdown (3Y) | −96.41% |
| Beta (3Y, vs SPY) | 3.22 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| TCRT | Alaunos Therapeutics, Inc. | $46.4M | — |
| IBO | IMPACT BIOMEDICAL INC. | $46.4M | — |
| BHST | BIOHARVEST SCIENCES INC. | $46.2M | — |
| CTOR | CITIUS ONCOLOGY, INC. | $50.3M | — |
| MCRB | Seres Therapeutics, Inc. | $46.0M | 7.5 |
| DWTX | Dogwood Therapeutics, Inc. | $52.1M | — |
| EDSA | Edesa Biotech, Inc. | $44.2M | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $52.7M | — |
| XLO | Xilio Therapeutics, Inc. | $52.9M | — |
| RANI | Rani Therapeutics Holdings, Inc. | $54.2M | — |
| FLNA | FILANA THERAPEUTICS, INC. |
| $42.7M |
| — |
| CNTX | Context Therapeutics Inc. | $54.3M | — |